ClearPoint Neuro’s mission is to improve and restore quality of life to patients and their families by enabling therapies for the most complex neurological disorders with pinpoint accuracy. Technology applications include deep-brain stimulation, laser catheters, biopsy, neuro-aspiration, and delivery of drugs, biologics, and gene and stem cell therapies to the brain. The ClearPoint® Neuro Navigation System is FDA cleared, CE-marked, and installed in 60 active clinical sites in the United States. The Company’s SmartFlow® Cannula is being used in partnership with 20+ individual biologics and drug delivery companies from preclinical research to late stage regulatory trials in the U.S., EU and Asia. To date, more than 3,600 cases have been performed and supported by the Company’s field-based clinical specialist team which offers support and services for our partners.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commericalization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, on Twitter at @PTCBio, and on LinkedIn.
Invicro is a leading contract research organization (CRO) providing biomarker solutions, core lab services, advanced analytics, and data informatic solutions. Invicro was founded in 2008 with offices, laboratories and clinics around the world that support leading pharmaceutical and biotechnology firms with their scientific research and clinical trials. Invicro’s multidisciplinary team provide scientific, regulatory, and operational expertise to support the discovery and development of life-changing therapeutics.
Invicro is a quantitative biomarker solutions provider that supports pharma with their drug discovery and development efforts.
Invicro’s team of scientific experts partner with clients to support non-clinical, translational, and clinical gene therapy research using a wide-range of imaging modalities, including a novel 3D tissue imaging method that will be presented on during the Overcoming the Challenges of Established & Novel Administration Routes track of the conference.
In vitro neural models are powerful tools to study neural function and complex disorders of the human nervous system. Maestro™ Pro and Edge bioelectronic assay systems from Axion BioSystems noninvasively monitor neural activity while preserving the complex structure and communication of neuronal networks. Simultaneously track neural activity and viability over days and months in up to 96 wells. Whether modeling neurological disease or evaluating gene therapies, these straightforward and easy-to-use systems offer a superior in vitro assay for studying disease-in-a-dish models.
PackGene Biotech, as an international AAV packaging supplier (one of the largest in the world), started up in Massachusetts. PackGene focuses on services of the rAAV-based gene therapy CDMO-from plasmid to rAAV in clinical-grade, rAAV packaging in research-grade, lentivirus packaging, vector cloning, etc. Our services aim to provide efficient, cost-effective, high-quality viral delivery solutions for gene and cell therapy, as well as clinical trials at various scale levels. PackGene has been building up its reputation by First-class Quality · Efficient Supply · Assured Service.
At Passage Bio we are on a mission to provide life-transforming gene therapies for patients with rare, monogenic CNS diseases that replace their suffering with boundless possibility, all while building lasting relationships with the communities we serve. Our company has established a strategic
collaboration and licensing agreement with the renowned University of Pennsylvania’s Gene Therapy Program to conduct our discovery and INDenabling preclinical work. This provides our team with enhanced access to a broad portfolio of gene therapy candidates and technical innovations
that we then pair with our clinical, regulatory, manufacturing and commercial expertise to rapidly advance our robust pipeline of optimized gene therapies into clinical testing. As we work with speed and tenacity, we are always mindful of patients who may be able to benefit from our therapies.